HeartBeam (BEAT) Stock News Today: FDA Clearance Ignites Rally, Analysts Lift Targets, and What Investors Are Watching Next (Dec. 17, 2025)
HeartBeam, Inc. received FDA 510(k) clearance on December 10 for its 12-lead ECG synthesis software after overturning a prior Not Substantially Equivalent decision on appeal. BEAT shares closed at $3.44 on December 16, up about 31% on heavy volume, with continued volatility in pre-market trading.